Cancer treatment could identify patients most likely to respond to cancer drugs
Tumours with high mtDNA mutations more likely to respond to Opdivo
Read More
Tag: Opdivo
Bristol Myers Squibb’s Opdivo recommended by NICE for malignant pleural mesothelioma patients
Armed forces veterans and people who were exposed to asbestos could benefit from the therapy
Read More
NICE recommends Opdivo as post-surgery treatment
The therapy will be used for specific muscle invasive urothelial cancer patients
Read More
Opdivo plus chemo improves event-free survival in NSCLC patients
Detailed results from the CheckMate-816 trial will be shared at an upcoming medical conference
Read More
NICE backs Opdivo for head and neck cancer
New evidence collected through the CDF shapes recommendation
Read More
EMA accepts BMS’ Opdivo application in oesophageal cancer
Phase III trial showed significant survival benefit over chemotherapy alone
Read More
MHRA approves Opdivo plus Yervoy for unresectable malignant pleural mesothelioma
First treatment to be approved for UK MPM patients for more than 15 years
Read More
EC green light for Opdivo plus Yervoy in metastatic colorectal cancer
Immunotherapy regimen approved to treat metastatic colorectal cancer after prior chemotherapy
Read More
Opdivo plus Yervoy scores NICE backing for certain bowel cancer patients
Immunotherapy combo approved for the treatment of advanced bowel cancer patients with rare MSI-H/dMMR mutations
Read More
Opdivo combos show OS benefit in advanced oesophageal cancer
Opdivo plus chemotherapy or Yervoy demonstrated overall survival benefit in PD-L1-positive and all-randomised populations
Read More
Opdivo, Yervoy combination approved to treat malignant pleural mesothelioma
Combination immunotherapy treatment approved in the EU for first-line treatment of adults with unresectable MPM
Read More
Opdivo plus Yervoy moves closer to EU approval for dMMR/MSI-H colorectal cancer
CHMP recommended EU approval for combination treatment in its May decisions
Read More
- Liverpool and McMaster University announce £300,000 strategic research partnership
- Study finds link between malaria parasites developing antimalarial drug resistance
- Researchers develop ‘digital twin’ heart models to better monitor PAH NHS patients
- Closed Loop and Pharmanovia investigate precision medicine combination in hypertension
- US study reveals interferon combinations cause lupus symptoms and affect treatment
